» Articles » PMID: 37647312

Characterization of Molecular Mechanisms Driving Merkel Cell Polyomavirus Oncogene Transcription and Tumorigenic Potential

Overview
Journal PLoS Pathog
Specialty Microbiology
Date 2023 Aug 30
PMID 37647312
Authors
Affiliations
Soon will be listed here.
Abstract

Merkel cell polyomavirus (MCPyV) is associated with approximately 80% of cases of Merkel cell carcinoma (MCC), an aggressive type of skin cancer. The incidence of MCC has tripled over the past twenty years, but there are currently very few effective targeted treatments. A better understanding of the MCPyV life cycle and its oncogenic mechanisms is needed to unveil novel strategies for the prevention and treatment of MCC. MCPyV infection and oncogenesis are reliant on the expression of the early viral oncoproteins, which drive the viral life cycle and MCPyV+ MCC tumor cell growth. To date, the molecular mechanisms regulating the transcription of the MCPyV oncogenes remain largely uncharacterized. In this study, we investigated how MCPyV early transcription is regulated to support viral infection and MCC tumorigenesis. Our studies established the roles of multiple cellular factors in the control of MCPyV gene expression. Inhibitor screening experiments revealed that the histone acetyltransferases p300 and CBP positively regulate MCPyV transcription. Their regulation of viral gene expression occurs through coactivation of the transcription factor NF-κB, which binds to the viral genome to drive MCPyV oncogene expression in a manner that is tightly controlled through a negative feedback loop. Furthermore, we discovered that small molecule inhibitors specifically targeting p300/CBP histone acetyltransferase activity are effective at blocking MCPyV tumor antigen expression and MCPyV+ MCC cell proliferation. Together, our work establishes key cellular factors regulating MCPyV transcription, providing the basis for understanding the largely unknown mechanisms governing MCPyV transcription that defines its infectious host cell tropism, viral life cycle, and oncogenic potential. Our studies also identify a novel therapeutic strategy against MCPyV+ MCC through specific blockage of MCPyV oncogene expression and MCC tumor growth.

Citing Articles

Advancing Treatment Options for Merkel Cell Carcinoma: A Review of Tumor-Targeted Therapies.

Nammour H, Madrigal K, Starling C, Doan H Int J Mol Sci. 2024; 25(20).

PMID: 39456853 PMC: 11507330. DOI: 10.3390/ijms252011055.


Merkel Cell Polyomavirus Antibody in Tumor and Plasma Specimens in Patients with Merkel Cell Carcinoma.

Schmocker R, Nodit L, Ward A, Lewis J, McLoughlin J, Enomoto L Ann Surg Oncol. 2024; 32(1):464-473.

PMID: 39373930 DOI: 10.1245/s10434-024-16292-8.


Polyomavirus ALTOs, but not MTs, downregulate viral early gene expression by activating the NF-κB pathway.

Salisbury N, Amonkar S, Landazuri Vinueza J, Carter J, Roman A, Galloway D Proc Natl Acad Sci U S A. 2024; 121(34):e2403133121.

PMID: 39141346 PMC: 11348336. DOI: 10.1073/pnas.2403133121.


Cellular Transformation by Human Cytomegalovirus.

Herbein G Cancers (Basel). 2024; 16(11).

PMID: 38893091 PMC: 11171319. DOI: 10.3390/cancers16111970.


Polyomavirus ALTOs, but not MTs, downregulate viral early gene expression by activating the NF-κB pathway.

Salisbury N, Amonkar S, Landazuri Vinueza J, Carter J, Roman A, Galloway D bioRxiv. 2024; .

PMID: 38826197 PMC: 11142227. DOI: 10.1101/2024.05.24.595774.


References
1.
Bowers E, Yan G, Mukherjee C, Orry A, Wang L, Holbert M . Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol. 2010; 17(5):471-82. PMC: 2884008. DOI: 10.1016/j.chembiol.2010.03.006. View

2.
Nelson D, Ihekwaba A, Elliott M, Johnson J, Gibney C, Foreman B . Oscillations in NF-kappaB signaling control the dynamics of gene expression. Science. 2004; 306(5696):704-8. DOI: 10.1126/science.1099962. View

3.
Wang R, Liu W, Helfer C, Bradner J, Hornick J, Janicki S . Activation of SOX2 expression by BRD4-NUT oncogenic fusion drives neoplastic transformation in NUT midline carcinoma. Cancer Res. 2014; 74(12):3332-43. PMC: 4097982. DOI: 10.1158/0008-5472.CAN-13-2658. View

4.
Zou Z, Huang B, Wu X, Zhang H, Qi J, Bradner J . Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA. Oncogene. 2013; 33(18):2395-404. PMC: 3913736. DOI: 10.1038/onc.2013.179. View

5.
Liu W, Krump N, Buck C, You J . Merkel Cell Polyomavirus Infection and Detection. J Vis Exp. 2019; (144). PMC: 6656558. DOI: 10.3791/58950. View